Skip to search formSkip to main contentSkip to account menu

Genasense

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
2005
2005
  • K. Garber
  • Nature Biotechnology
  • 2005
  • Corpus ID: 44373240
Surging numbers of therapeutic proteins and small molecules, rationally designed to trigger cell death, are entering the clinic… 
Review
2004
Review
2004
Many retinal degenerations both inherited and induced are characterized by a loss of vision that is associated with death of… 
Review
2004
Review
2004
Purpose of review Recent case-control studies and metaanalyses have attempted to quantify the risks associated with individual… 
Highly Cited
2004
Highly Cited
2004
Purpose: To assess the feasibility of administering oblimersen sodium, a phosphorothioate antisense oligonucleotide directed to… 
Highly Cited
2003
Highly Cited
2003
Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia and has been associated with unfavorable… 
Review
2002
Review
2002
The components of the apoptotic program are targets for anticancer therapy. Bcl-2 protein inhibits apoptosis and confers… 
Highly Cited
2001
Highly Cited
2001
PURPOSE Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and… 
Review
2001
Review
2001
  • D. Banerjee
  • Current opinion in investigational drugs
  • 2001
  • Corpus ID: 23060155
Genasense (formerly known as G-3139), an antisense oligonucleotide specific for Bcl-2, is under development by Genta as an iv… 
Highly Cited
2000